Provided by Tiger Trade Technology Pte. Ltd.

HUTCHMED

19.370
-0.460-2.32%
Volume:4.54M
Turnover:88.69M
Market Cap:16.89B
PE:4.75
High:20.100
Open:19.770
Low:19.240
Close:19.830
52wk High:28.800
52wk Low:15.570
Shares:872.00M
HK Float Shares:872.00M
Volume Ratio:0.97
T/O Rate:0.52%
Dividend:- -
Dividend Rate:- -
EPS(LYR):4.076
ROE:1.46%
ROA:-1.24%
PB:1.71
PE(LYR):4.75
PS:3.92

Loading ...

Hong Kong Stocks Edge Lower on Monday Amid Middle East Tensions; HUTCHMED Falls 2%

MT Newswires Live
·
Yesterday

Hutchmed Says Savolitinib Plus AstraZeneca’s Tagrisso Extends PFS in China Phase III Sanovo Lung Cancer Trial

Reuters
·
Yesterday

HUTCHMED Sees Positive High Level Results in Lung Cancer Drug Combo Trial

MT Newswires Live
·
Yesterday

Hutchmed (China) - Announces Positive Results from Sanovo China Phase Trial in Nsclc Patients

THOMSON REUTERS
·
Yesterday

Hutchmed Announces Sanovo Trial Demonstrated Significant Progression-Free Survival Benefit of Orpathys® Plus Tagrisso® in Treatment-NaÏVe Patients with Met-Overexpressing Egfr-Mutated Lung Cancer in China

THOMSON REUTERS
·
Yesterday

Sector Update: Health Care Stocks Mixed Pre-Bell Friday

MT Newswires Live
·
Aug 28

Hutchmed (China) Announces NMPA Conditional Approval for ATLED in China

Reuters
·
Aug 28

HUTCHMED's Cholangiocarcinoma Drug Application Gets Conditional Nod in China

MT Newswires Live
·
Aug 28

Hutchmed (China) - Fanregratinib to be Marketed in China as Atled

THOMSON REUTERS
·
Aug 28

Hong Kong Market Movers: Mixue's Revenue Reaches RMB 15.2 Billion in First Half, Global Store Network Expands

Stock News
·
Aug 28

HUTCHMED Secures NMPA Conditional Approval for ATLED® (Fanregratinib) Targeting FGFR2-Altered Intrahepatic Cholangiocarcinoma

Bulletin Express
·
Aug 28

HUTCHMED secures NMPA approval for ATLED to address FGFR2-altered intrahepatic cholangiocarcinoma

Stock News
·
Aug 28

Hutchmed (China) - Announces Nmpa Conditional Approval for Atled (Fantegratinib) in China

THOMSON REUTERS
·
Aug 28

Hutchmed Says China NMPA Approves ATLED for FGFR2-Altered Intrahepatic Cholangiocarcinoma

Reuters
·
Aug 28

Hutchmed Announces Nmpa Approval for Atled® (Fanregratinib) for the Treatment of Patients with Fgfr2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma

THOMSON REUTERS
·
Aug 28

Dow Jones Top Company Headlines at 1 PM ET: Walmart Shares Slump on Weakest Sales Growth in over Six Years | Super ...

Dow Jones
·
Aug 21

Dow Jones Top Company Headlines at 7 am ET: Alibaba Posts Weaker Earnings Amid Heavy AI Investments | Deere's ...

Dow Jones
·
Aug 20

Hutchmed (China) Ltd: Insolvency Proceedings Remain Ongoing, Outcome of Proceedings is not Known to Company as at Date of This Announcement

THOMSON REUTERS
·
Aug 18

Hutchmed (China) - S.d. Sight Diagnostics Subject to Insolvency Proceedings in Israel

THOMSON REUTERS
·
Aug 18

Hutchmed (China) - Amount Involved in Insolvency Proceedings is Nis3,057,876 (us$1,019,292)

THOMSON REUTERS
·
Aug 18